Cited by — Correction: First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590 | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Correction: First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.
No admitted local citation edges point to this work yet.
